New hope: drug may prevent dangerous reactions to cancer immunotherapy

NCT ID NCT07567014

Not yet recruiting Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatment to see if it reduces these risks. The goal is to make this powerful therapy safer for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma large B-cell lymphoma plasma cell myeloma primary mediastinal large B-cell lymphoma cytokine release syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA (LBCL) MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

NYU Langone Health - Long Island

Mineola, New York, 11501, United States
NYU Langone Health Perlmutter Cancer Center - Manhattan

Manhattan, New York, 10016, United States
NYU Langone Health Perlmutter Cancer Center - Sunset Park

Brooklyn, New York, 11220, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.